{"id":49231,"date":"2022-10-06T07:01:39","date_gmt":"2022-10-06T05:01:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/"},"modified":"2022-10-06T07:01:39","modified_gmt":"2022-10-06T05:01:39","slug":"benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/","title":{"rendered":"BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nTwo additional novel AI-generated targets for chronic kidney disease and idiopathic pulmonary fibrosis discovered using the Benevolent Platform\u2122 selected to enter AstraZeneca\u2019s drug discovery portfolio\n<\/li>\n<li>\nTotal of five targets selected to date for portfolio-entry in the collaboration, with the potential for future development milestones and sales-based royalty revenues for BenevolentAI\n<\/li>\n<\/ul>\n<p>LONDON&#8211;(BUSINESS WIRE)&#8211;Regulatory News:\n<\/p>\n<p>\nBenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, today announces that AstraZeneca, a global, science-led biopharmaceutical company, has selected an additional two novel targets to enter its drug portfolio, for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF), resulting in two milestone payments to BenevolentAI.\n<\/p>\n<p>\nThe long-term collaboration, initiated in 2019, combines BenevolentAI\u2019s proprietary AI-enabled drug discovery platform, the Benevolent Platform\u2122, with AstraZeneca\u2019s disease expertise to identify novel targets. The Platform is disease agnostic, meaning it can be applied to any disease and is capable of rapidly generating novel targets at scale. These latest milestones provide additional validation for BenevolentAI\u2019s disease-agnostic approach, which has so far delivered five novel targets to AstraZeneca\u2019s portfolio, two for CKD and three for IPF. The collaboration was also expanded for a further three years into two new disease areas \u2014 heart failure and systemic lupus erythematosus \u2014 in January 2022.\n<\/p>\n<p>\nThrough the collaboration, BenevolentAI integrates AstraZeneca\u2019s data into its biomedical Knowledge Graph, which has the ability to rapidly normalise and contextualise a diverse range of external and internal data from numerous sources including, but not limited to, scientific literature, patents, genetics, chemistry and clinical trials. BenevolentAI and AstraZeneca scientists work side-by-side, using the Platform and Knowledge Graph to interrogate underlying disease mechanisms, frame and test hypotheses and rapidly identify novel targets. New knowledge generated through the disease programmes is also fed back into the Platform, improving the quality of future drug target predictions.\n<\/p>\n<p>\n<b>Joanna Shields, Chief Executive Officer at BenevolentAI, commented: <\/b><i>\u201cWe are pleased that AstraZeneca has selected a further two novel targets from our collaboration to enter its portfolio. These milestones provide repeated validation of BenevolentAI\u2019s drug discovery Platform, which has demonstrated significant momentum in identifying novel targets across a range of therapeutic indications. We look forward to further successes in our collaboration.\u201d<\/i>\n<\/p>\n<p>\n<b>Mene Pangalos, Executive Vice President, BioPharmaceuticals R&amp;D, AstraZeneca, commented<\/b>: <i>&#8220;In order to deliver the next wave of life-changing medicines it is important we identify the right drug targets that can transform disease. Our ongoing collaboration with BenevolentAI is helping us to uncover novel rare variants of complex diseases, such as IPF and CKD. By combining the power of AI with human expertise we are bringing new drug targets into our portfolio.\u201d<\/i>\n<\/p>\n<p>\n<b>ENDS<\/b>\n<\/p>\n<p>\n<b>About BenevolentAI<\/b>\n<\/p>\n<p>\nBenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform\u2122 powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>BenevolentAI:<br \/>\n<br \/><\/b><b>Media:<\/b><br \/>Rajin Kang \u2013 VP Communications<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#58;&#114;&#97;&#106;in&#46;k&#x61;&#x6e;&#x67;&#x40;&#x62;&#x65;&#110;&#101;&#118;&#111;&#108;ent&#x2e;&#x61;&#x69;\" rel=\"nofollow noopener\" shape=\"rect\">&#x72;&#x61;&#x6a;&#x69;&#x6e;&#46;&#107;&#97;&#110;g&#64;b&#x65;&#x6e;&#x65;&#x76;&#x6f;&#x6c;&#101;&#110;&#116;&#46;ai<\/a>\n<\/p>\n<p>\n<b>Investors:<\/b><br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;t&#x6f;&#x3a;&#x69;&#110;&#118;e&#x73;&#x74;&#x6f;&#114;&#115;&#64;&#x62;&#x65;&#x6e;&#101;&#118;o&#x6c;&#x65;&#x6e;&#116;&#46;a&#x69;\" rel=\"nofollow noopener\" shape=\"rect\">&#105;&#x6e;&#x76;e&#115;&#x74;o&#114;&#x73;&#64;&#98;&#x65;n&#101;&#x76;&#x6f;&#108;&#x65;&#x6e;t&#46;&#x61;i<\/a><br \/>Fleur Wood \u2013 VP Investor Relations<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;t&#111;&#x3a;&#x66;l&#101;&#x75;&#x72;&#46;&#119;&#x6f;&#x6f;d&#64;&#x62;&#x65;n&#101;&#118;&#x6f;&#x6c;e&#110;&#x74;&#x2e;a&#105;\" rel=\"nofollow noopener\" shape=\"rect\">&#x66;&#x6c;&#101;&#117;&#114;&#46;&#x77;&#x6f;&#x6f;&#100;&#64;be&#x6e;&#x65;&#x76;&#111;&#108;e&#x6e;&#x74;&#x2e;&#97;&#105;<\/a>\n<\/p>\n<p>\n<b>FTI Consulting:<\/b><br \/>Ben Atwell, Simon Conway, Victoria Foster Mitchell<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;&#108;&#x74;&#x6f;:&#x42;&#x65;n&#101;&#x76;o&#108;&#x65;n&#116;&#x41;I&#64;&#x66;t&#105;&#x63;&#x6f;&#110;&#x73;&#x75;&#108;&#x74;&#x69;n&#x67;&#x2e;c&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x42;&#x65;&#x6e;&#x65;&#x76;&#111;&#108;&#101;&#110;tAI&#x40;&#x66;&#x74;&#x69;&#x63;&#x6f;&#110;&#115;&#117;lti&#x6e;&#x67;&#x2e;&#x63;&#x6f;&#x6d;<\/a><br \/>+44 (0) 20 3727 1000\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Two additional novel AI-generated targets for chronic kidney disease and idiopathic pulmonary fibrosis discovered using the Benevolent Platform\u2122 selected to enter AstraZeneca\u2019s drug discovery portfolio Total of five targets selected to date for portfolio-entry in the collaboration, with the potential for future development milestones and sales-based royalty revenues for BenevolentAI LONDON&#8211;(BUSINESS WIRE)&#8211;Regulatory News: BenevolentAI (Euronext &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49231","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Two additional novel AI-generated targets for chronic kidney disease and idiopathic pulmonary fibrosis discovered using the Benevolent Platform\u2122 selected to enter AstraZeneca\u2019s drug discovery portfolio Total of five targets selected to date for portfolio-entry in the collaboration, with the potential for future development milestones and sales-based royalty revenues for BenevolentAI LONDON&#8211;(BUSINESS WIRE)&#8211;Regulatory News: BenevolentAI (Euronext ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-06T05:01:39+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca\",\"datePublished\":\"2022-10-06T05:01:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\\\/\"},\"wordCount\":589,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\\\/\",\"name\":\"BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-10-06T05:01:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/","og_locale":"en_US","og_type":"article","og_title":"BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca - Pharma Trend","og_description":"Two additional novel AI-generated targets for chronic kidney disease and idiopathic pulmonary fibrosis discovered using the Benevolent Platform\u2122 selected to enter AstraZeneca\u2019s drug discovery portfolio Total of five targets selected to date for portfolio-entry in the collaboration, with the potential for future development milestones and sales-based royalty revenues for BenevolentAI LONDON&#8211;(BUSINESS WIRE)&#8211;Regulatory News: BenevolentAI (Euronext ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-06T05:01:39+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca","datePublished":"2022-10-06T05:01:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/"},"wordCount":589,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/","url":"https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/","name":"BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-10-06T05:01:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-achieves-further-milestones-in-ai-enabled-target-identification-collaboration-with-astrazeneca\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49231"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49231\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}